14:10 , Apr 3, 2018 |  BC Innovations  |  Targets & Mechanisms

Sensor sensibility

Zhijian “James” Chen’s discovery of the DNA sensor cGAS revealed the missing link between cytosolic DNA and innate immune activation, paving the way for immunotherapies targeting the cGAS-STING pathway. The lowest-hanging fruit has been in...
12:32 , Apr 3, 2018 |  BC Extra  |  Preclinical News

Lurie Prize awarded for cGAS-STING discovery

The Foundation for the National Institutes of Health (FNIH) announced Tuesday it has awarded this year's Lurie Prize in Biomedical Sciences to Zhijian “James” Chen for the discovery of the cytosolic DNA sensor cGAMP synthase...
01:24 , Jan 18, 2018 |  BC Extra  |  Preclinical News

Chromosomal instability can trigger metastasis via STING activity

A paper published in...
01:19 , Jan 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Age-related macular degeneration (AMD) Patient sample, cell culture and mouse studies suggest inhibiting cGAS, CASP4, GSDMD, IFNB1, IFNAR1, IRF3 or STAT2 could help treat geographic atrophy. In tissue samples from patients, levels of cGAS,...
20:05 , Nov 6, 2017 |  BC Extra  |  Preclinical News

Team identifies new targets to treat myocardial infarction

In a paper published Monday in...
19:51 , Nov 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Mouse studies suggest inhibiting IRF3, IFNAR1, or cGAS could help treat MI. In infarcted heart tissue from a mouse model of MI, IRF3 expression was higher than in heart tissue from...
19:58 , Sep 26, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer; breast cancer; colorectal cancer Patient sample and mouse studies suggest dual inhibition of miR-25 and miR-93 or promoting cGAS expression could help treat brain, breast and colorectal cancers. In patients, high brain...
13:01 , Mar 17, 2017 |  BC Week In Review  |  Clinical News

Latuda: Ph III Illuminate data

Top-line data from the double-blind, international Phase III Illuminate trial in about 471 patients ages 10-17 with depression associated with bipolar I disorder showed that flexible dosing with once-daily 20-80 mg Latuda met the primary...
07:00 , Jul 28, 2016 |  BC Innovations  |  Targets & Mechanisms

Making sense of sensors

Two new pathways are emerging as viable options for harnessing nucleic acid sensors in immuno-oncology, offering an alternative to the toll-like receptors (TLRs) that paved the way. By activating STING or RIG-I , researchers are...
07:00 , May 21, 2015 |  BC Innovations  |  Product R&D

Aduro's STING

Aduro Biotech Inc. 's preclinical STING agonists have caught the eye of pharmas for their ability to stimulate immunity in distal tumors, which suggests the compounds might be among the first immunotherapy agents for metastases....